Azienda Sanitaria Rummo, Benevento, Division of Medical Oncology Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01405573
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

sorafenib (nexavar) (1 trial)

Drugs in Phase 2 Trials (1)

panitumumab (vectibix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Colorectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2